SCM
BDTX icon

Sterling Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Sterling Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76K Buy
+951
New +$2.33K ﹤0.01% 3024
2025
Q2 		– Sell
-247
Closed -$383 – 3279
2025
Q1 		$383 Sell
247
-207
-46% -$434 ﹤0.01% 3008
2024
Q4 		$972 Buy
454
+390
+609% +$1.12K ﹤0.01% 2946
2024
Q3 		$278 Buy
+64
New +$348 ﹤0.01% 3050

Other funds holding BDTX

DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
BCM
Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Sterling Capital Management's BDTX Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 951 shares worth $1.76K. The stake represents ﹤0.01% of the portfolio and ranks #3024 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in BDTX as recently as Q1 2025.

Sterling Capital Management first reported a position in BDTX in Q3 2024 and has held it in 4 quarters since. 11 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Sterling Capital Management held 951 shares of Black Diamond Therapeutics worth $1.76K as of Q2 2026.
  • Black Diamond Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3024 holding.
  • Sterling Capital Management first reported a position in Black Diamond Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 11 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.